Home › Research › Biomarkers
Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases
Sanchez E, Coughlan GT, Wilkinson T, Ramirez J, Mirza SS, Baril AA, Dilliott AA, Frank A et al.. Neurology, 2025-03-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background and objectives Plasma biomarkers of Alzheimer disease (AD), neuroinflammation, and neurodegeneration are increasingly being used in clinical trials for diagnosis and monitoring of dementia. However, their association with longitudinal structural brain MRI changes, an important outcome measure across neurodegenerative and cerebrovascular diseases, is less known. We investigated how baseline plasma biomarkers reflect MRI markers of progression over time in patients with neurodegenerative and cerebrovascular diseases. Methods This longitudinal cohort study included patients from the Ontario Neurodegenerative Disease Research Initiative diagnosed with AD or mild cognitive impairment (AD/MCI), Parkinson disease (PD), frontotemporal dementia spectrum disorders (FTD), or cerebrovascular disease (CVD), followed annually for 2 years. Recruitment took place at specialized university-based dementia, movement disorders, and/or stroke clinics in the province of ON, Canada. MRI outcomes included markers of cerebral atrophy (ventricular CSF and regional gray matter volumes) and of small vessel disease pathology (white matter hyperintensity [WMH], perivascular spaces, and lacunar volumes). Hemorrhagic markers at baseline were also included. Plasma levels of glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau181 and tau217 (p-tau181, p-tau217), and β-amyloid (Aβ 42/40 ) were quantified from blood samples collected at baseline using Simoa and used as predictors in linear mixed models adjusted for time (months), age, sex, apolipoprotein E ( APOE )-ε4 carrier status, kidney function, vascular risk factors, microtubule-associated protein tau ( MAPT ) diplotypes, waist-hip circumference ratio, and disease duration. Results We analyzed 1,240 MRIs from 473 patients (age: 69.2 ± 7.4 [range: 49-87]; 32.8% women). Elevated baseline levels of GFAP, NfL, p-tau181, and p-tau217, and to a lesser extent decreased levels of Aβ 42/40 , were significantly associated with more cerebral atrophy and WMH burden at baseline (| B | = 0.02 to 1.69, p = 0.044 to B | = 0.001 to 0.028, p = 0.049 to Discussion Selected plasma biomarkers seem useful as prognosis and monitoring tools of longitudinal imaging changes within real-world populations of neurodegenerative and/or cerebrovascular diseases, and provide insight into overlap across diseases in shared pathologic burden.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 1,240 participants. In 473 patients with neurodegenerative or cerebrovascular diseases followed for 2 years, elevated baseline GFAP, NfL, p-tau181, and p-tau217 were associated with more brain atrophy and white matter hyperintensity burden. Reported effect size: 32.8%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sanchez, E., Coughlan, G. T., Wilkinson, T., Ramirez, J., Mirza, S. S., Baril, A. A., et al. (2025). Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases. Neurology. https://doi.org/10.1212/wnl.0000000000213438
Vancouver
Sanchez E, Coughlan GT, Wilkinson T, Ramirez J, Mirza SS, Baril AA, et al. Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases. Neurology. 2025. doi:10.1212/wnl.0000000000213438. PMID: 40063856.
BibTeX
@article{sanchez2025-40063856,
author = {Sanchez, E. and Coughlan, G. T. and Wilkinson, T. and Ramirez, J. and Mirza, S. S. and Baril, A. A. and Dilliott, A. A. and Frank, A. and others},
title = {{Association of Plasma Biomarkers With Longitudinal Atrophy and Microvascular Burden on MRI Across Neurodegenerative and Cerebrovascular Diseases}},
journal = {Neurology},
year = {2025},
doi = {10.1212/wnl.0000000000213438},
pmid = {40063856},
url = {https://doi.org/10.1212/wnl.0000000000213438}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results We analyzed 1,240 MRIs from 473 patients (age: 69.2 ± 7.4 [range: 49-87]; 32.8% women).
- Elevated baseline levels of GFAP, NfL, p-tau181, and p-tau217, and to a lesser extent decreased levels of Aβ 42/40 , were significantly associated with more cerebral atrophy and WMH burden at baseline (| B | = 0.02 to 1.69, p = 0.044 to <0.001) and with progression over time (| B | = 0.001 to 0.028, p = 0.049 to <0.001) in the pooled disease-agnostic group.
Why it matters
In 473 patients with neurodegenerative or cerebrovascular diseases followed for 2 years, elevated baseline GFAP, NfL, p-tau181, and p-tau217 were associated with more brain atrophy and white matter hyperintensity burden. This is an observational biomarker-imaging study and does not test any treatment, cure, or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcohort study
- Participants1,240
- Effect size32.8%
- Evidence strengthModerate
How this study scored 70/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 67 of the 96 points we could judge it on, which is 70 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,240 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 32 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 20.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 32 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 49 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40063856) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 67 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 67 of the 96 points we could judge it on is 70 out of 100. |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wnl.0000000000213438
- PubMed: 40063856
- Original source →
- Free full text: research.ed.ac.uk →
Full text: free to read — Unpaywall lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 25.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.